Comparison · NCT02540993-0a1cce33
Finerenone vs Placebo: All-cause Mortality
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Finerenone vs Placebo: All-cause Mortality. Trial comparisons, record NCT02540993-0a1cce33. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02540993-0a1cce33
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0773 | 0.068 | 0.0877 | wilson | |
| Risk in group 2 | 0.0859 | 0.0761 | 0.0968 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00858 | -0.0229 | 0.00569 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.9 | 0.756 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | 0.892 | 0.737 | 1.08 | log | |
| Number needed to treat, for one fewer participant with the outcome on Finerenone than on Placebo | 117 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Finerenone | Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy | 219 | 2,833 | OG000 |
| Group 2 | Placebo | Participants received matching placebo once daily in addition to standard of care therapy | 244 | 2,841 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- All-cause Mortality
- Description
Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.
- Time frame
- From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months
- Population
- Full analysis set
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
- NCT number
- NCT02540993
- Phases
- PHASE3
- Conditions
- Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Lead sponsor
- Bayer
- Results first posted
- 2021-07-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02540993?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02540993-0a1cce33